Longeveron (NASDAQ: LGVN) — Perfil da empresa, notícias e dados financeiros
Longeveron develops cellular therapies for aging-related conditions, aiming to improve health and longevity through innovative research.
Longeveron
Longeveron (NASDAQ:LGVN) is a biotechnology firm focused on developing cellular therapies for aging-related and life-threatening conditions. The company's innovative research is dedicated to harnessing the potential of regenerative medicine to address the unmet needs of diseases such as aging frailty, metabolic disorders, and Alzheimer’s disease, among others. With a commitment to improving human health and longevity, Longeveron continues to advance its clinical studies and expand its pipeline of therapeutic candidates. The firm aims to lead the way in cellular therapy development, focusing on rigorous science and clinical trials to bring new treatments from the lab to the patients who need them most.
Resumo
Operações
Produtos e/ou serviços de Longeveron
- Lomecel-B, a stem cell therapy aimed at treating aging-related conditions and diseases.
- Clinical trials for Alzheimer's disease, focusing on slowing progression using cellular therapy.
- Development of treatments targeting the rare pediatric condition Hypoplastic Left Heart Syndrome.
- Research into therapies for Aging Frailty, intending to improve physical function and quality of life.
- Investigative treatments for Metabolic Syndrome, designed to address the root causes of this complex condition.
- COVID-19 treatment research, exploring stem cell-based therapies to mitigate severe symptoms.
equipe executiva do Longeveron
- Joshua Michael HareCo-Founder, Chief Science Officer & Executive Chairman
- Paul T. LehrGeneral Counsel & Secretary
- Stephen H. WillardCEO & Director
- Nirav Suresh JhaveriCFO and Principal Financial & Accounting Officer
- Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls
- Nataliya AgafonovaChief Medical Officer
- Lisa McClain-MossVice President of Manufacturing
- Marie WashburnVP & Corporate Controller
- Brian G RashVice President of Research & Discovery
Últimas notícias sobre a Longeveron
Principais indicadores financeiros
Resultados divulgados pela Longeveron , em USD.
- Cap. de mercado
- 5,7 mi
- Receita (TTM)
- 1,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -10.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,2 mi | -23,3 mi | -22,7 mi | |
| 2,4 mi | -16,5 mi | -16 mi | |
| 709 mil | -21 mi | -21,4 mi | |
| 1,2 mi | -18 mi | -18,8 mi |